Article Abstract

Could WNT inhibitors really knock on the treatment door of small cell lung cancer?

Authors: Laura Esteller, Susana Hernández, Fernando Lopez-Rios, Jordi Remon


Small cell lung cancer (SCLC) is an exceptionally lethal cancer for which new therapeutic approaches are needed. Despite over 30 years of clinical research, little progress has been made in the management of SCLC, and outcomes remain poor with median overall survival (OS) of 29 months with chemo-radiotherapy and prophylactic cranial irradiation in limited stage SCLC, and of 9–11 months in the metastatic setting with platinum-etoposide, even in the most recent randomized clinical trials with chemotherapy alone (1,2).